Oil and Gas Stocks Trading Alert; Aroway Energy Inc. (TSX.V: ARW) Continues Drilling Success in 2011
CALGARY, ALBERTA - March 22, 2011 (Investorideas.com Newswire) - AROWAY ENERGY INC. (TSX VENTURE:ARW; PINK SHEETS:ARWJF) (the "Company") Further to its March 3, 2011 news release, the Company provides the following update on its 2011 joint venture drilling operations in the Peace River Arch area of Alberta. The Company's first well of the 2011 exploration program has now been drilled, cased and completed and is awaiting pipeline tie-in. This multi-prospect exploration well was drilled to an approximate depth of 2300 meters targeting the Leduc formation. The Company is paying 50% of all costs associated with this well to earn a 50% interest in the well. Upon completion of the tie-in to its joint venture partner's pipeline and facilities, stabilized production numbers for this successful well will be released.
Drilling operations have begun on the Company's second Leduc exploration well. The multi-prospective well will be drilled to an approximate depth of 2260 meters targeting the Leduc formation. The 3D seismically defined multi-zone prospective well is also being operated by the Company's joint venture farm in partner with the Company paying 75% of all costs associated with this well to earn a 50% interest in the well. This exploration well is expected to take approximately 10 days to reach total depth.
These are the first two of a possible six wells planned for the joint venture partnership's 2011 drill program. All of the planned exploration and/or development wells to be drilled are defined by 3D seismic, have multi-zone prospectivity, and are close to infrastructure.
About Aroway Energy Inc.:
Aroway Energy Inc. is junior oil and gas exploration Company focused on high working interest non-operated oil and gas exploration prospects. Aroway is currently participating in two exploration wells which are programmed to a total depth into the Leduc formation in the Peace River Arch area of Alberta. The Company will pay 75% of all costs to earn 50% of all revenues in the exploration program.
ON BEHALF OF AROWAY ENERGY INC.
Chris Cooper, President
BOEs may be misleading, particularly if used in isolation. A BOE conversion ratio of 6 Mcf: 1bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Aroway Energy Inc
Judy-Ann Pottinger
Aroway Energy Inc.
(604) 304-4090 or Cell: (604) 617-5290
(604) 909-2679 (FAX)
jpottinger@arowayenergy.com
www.arowayenergy.com
(647) 258-3311 or Toll Free: (888) 258-3323
Investor Cubed Inc.
(416) 363-7977 (FAX)
info@investor3.ca
Disclosure: ARW is a paid advertising client on Investorideas.com and our energy, natural gas, and oil and gas portals.
Tuesday, March 22, 2011
Security Stocks; Visualant (OTCBB:VSUL) Subsidiary TransTech Systems Obtains Exclusive Department of Homeland Security Distribution Deal
SEATTLE - March 22, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color-based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems has become the exclusive distributor to the US Federal Government of a new custom-developed proximity card programmer for use on their newly mandated identification cards.
This programmer will allow those agencies to program both 125 kHz and 13.56 MHz access control cards to match the current format in use at any particular facility, and will eliminate the expense for those agencies to have the cards individually programmed by the proximity chip manufacture prior to delivery. Agencies can now order standard card stock for all their facilities and not be required to purchase different formats for different locations as necessary prior to the development of this new device. As well, this offering will allow more flexibility in time and budget to the many agencies that are being forced to consider expensive upgrades to their existing access control systems in order to comply with the HSPD-12 presidential directive that all federal employees carry a specific type of access card, referred to as Personal Identity Verification ("PIV").
Jim Gingo, TransTech President stated, "This product will be supplied to the Department of Homeland Security ("DHS") on an exclusive basis. This order is indicative of our ongoing commitment to and support of the many DHS agencies with which we work with the ultimate goal of assisting them to save money and better work within the constraints of severely reduced funding."
Ron Erickson, Visualant CEO said, "TransTech has a respected reputation for excellence in the security and authentication marketplace. The work that Jim Gingo and his team perform for our nation’s government is first rate and helps provide the security that we demand for our country."
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
SEATTLE - March 22, 2011 (Investorideas.com Defense Newswire) - Visualant, Inc. (OTCBB: VSUL), a pioneer provider of industry-leading color-based identification and diagnostic solutions, an emerging leader in security and authentication systems technology and distributor of a wide variety of security solutions through its wholly owned subsidiary, TransTech Systems, Inc., is pleased to announce that TransTech Systems has become the exclusive distributor to the US Federal Government of a new custom-developed proximity card programmer for use on their newly mandated identification cards.
This programmer will allow those agencies to program both 125 kHz and 13.56 MHz access control cards to match the current format in use at any particular facility, and will eliminate the expense for those agencies to have the cards individually programmed by the proximity chip manufacture prior to delivery. Agencies can now order standard card stock for all their facilities and not be required to purchase different formats for different locations as necessary prior to the development of this new device. As well, this offering will allow more flexibility in time and budget to the many agencies that are being forced to consider expensive upgrades to their existing access control systems in order to comply with the HSPD-12 presidential directive that all federal employees carry a specific type of access card, referred to as Personal Identity Verification ("PIV").
Jim Gingo, TransTech President stated, "This product will be supplied to the Department of Homeland Security ("DHS") on an exclusive basis. This order is indicative of our ongoing commitment to and support of the many DHS agencies with which we work with the ultimate goal of assisting them to save money and better work within the constraints of severely reduced funding."
Ron Erickson, Visualant CEO said, "TransTech has a respected reputation for excellence in the security and authentication marketplace. The work that Jim Gingo and his team perform for our nation’s government is first rate and helps provide the security that we demand for our country."
About Visualant, Inc.
Visualant, Inc. (OTCBB: VSUL) develops low-cost, high speed, light-based security and quality control solutions for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and process control applications. Our patent-pending technology uses controlled illumination with specific bands of light, to establish a unique spectral signature for both individual and classes of items. When matched against existing databases, these spectral signatures allow precise identification and authentication of any item or substance. This breakthrough optical sensing and data capture technology is called Spectral Pattern Matching ("SPM"). SPM technology can be miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and can be combined in the same package as a bar-code or biometric scanner.
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security and authentication solutions to security and law enforcement markets throughout the United States.
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visualant, Inc. (OTCBB:VSUL) Featured showcase company on Investorideas.com and related security portals and blogs
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)
Visit the showcase page: http://www.investorideas.com/CO/VSUL/
Disclaimer: Visualant, Inc. (OTCBB:VSUL) is a paid advertising featured showcase company on Investorideas.com and related security portals and blogs. (2500 per month)
Consumer/ Retail Stocks; YesDTC (OTCBB:YESD) Receives $500,000 Credit Line to Expand WordSmart Advertising, Driving Additional Revenue Growth -- Investor Update
SAN FRANCISCO - March 22, 2011 (Investorideas.com newswire) - YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, today announced it has obtained a new credit line of up to $500,000 for media purchasing. The credit line is being utilized beginning this week to finance a sizably increased budget for advertising the Company's flagship WordSmart product line, a development that holds significance given that over 90% of the WordSmart revenues come from television advertising.
"This is a very important event for us," commented Joseph Noel, CEO of YesDTC. "Since acquiring the WordSmart show, we have been producing a solid media efficiency ratio (MER) which corresponds to revenue generated for each dollar spent on media. With a strong, reliable MER, the direct response revenue generation model becomes relatively simple -- spending more on media will produce more revenues." Mr. Noel continued, "With this new financing resource, we will be able to further increase the airing frequency of the thirty-minute WordSmart infomercial hosted by Alex Trebek of Jeopardy! Next week, we plan to double our WordSmart media spending, with an almost additional doubling the following week."
Mr. Noel, continued, "While these events are very exciting, and given the WordSmart program will likely be a significant revenue producer this year, we do not think it will be our biggest revenue producer. We are planning to launch our MotorBooster engine conditioner product during the Memorial Day weekend and, considering the rising price of fuel, we believe revenue from this new fuel saving product could easily surpass the robust results produced by WordSmart. Additionally, our PureSleep anti-snoring product, which launched inChina
a few days ago, could represent meaningful upside potential. We believe this product is well positioned in the marketplace considering that it is an FDA cleared device made from U.S. produced plastics that is now going head-to-head with vastly inferior Chinese designed and manufactured products at the same pricing level."
"Over the next few weeks, we also plan to restart the advertising program for the MediPendant personal medical alarm in conjunction with our joint venture partner, Medical Alarm Concepts Holding, Inc. (OTCQB:MDHI). Recent tests showed very strong sales. We have re-cut the 120-second MediPendant commercial into a 60-second format, which we believe will produce even better results. We are also proceeding with the NutriFusion product via an upcoming retail placement in up to 300 Mannings drugstores in Hong Kong. We remain very excited about our growth prospects this year," concluded Mr. Noel.
YesDTC's growing product portfolio currently includes the NutriFusion line of easy-to-consume capsule and chewable nutraceutical supplement products; WordSmart, the knowledge and vocabulary building program sponsored by Alex Trebek of Jeopardy!; PureSleep Asia, the U.S. FDA-cleared anti-snoring dental device for the treatment of snoring, and MediPendant(TM), the only speak and listen through the pendant medical alarm system. The Company's infomercials for MediPendant and WordSmart can be seen at www.medipendant.com, and http://www.vimeo.com/16363930, respectively. More information on NutriFusion can be seen at www.nutrifusion.com
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc.
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world
lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising .
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
SAN FRANCISCO - March 22, 2011 (Investorideas.com newswire) - YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, today announced it has obtained a new credit line of up to $500,000 for media purchasing. The credit line is being utilized beginning this week to finance a sizably increased budget for advertising the Company's flagship WordSmart product line, a development that holds significance given that over 90% of the WordSmart revenues come from television advertising.
"This is a very important event for us," commented Joseph Noel, CEO of YesDTC. "Since acquiring the WordSmart show, we have been producing a solid media efficiency ratio (MER) which corresponds to revenue generated for each dollar spent on media. With a strong, reliable MER, the direct response revenue generation model becomes relatively simple -- spending more on media will produce more revenues." Mr. Noel continued, "With this new financing resource, we will be able to further increase the airing frequency of the thirty-minute WordSmart infomercial hosted by Alex Trebek of Jeopardy! Next week, we plan to double our WordSmart media spending, with an almost additional doubling the following week."
Mr. Noel, continued, "While these events are very exciting, and given the WordSmart program will likely be a significant revenue producer this year, we do not think it will be our biggest revenue producer. We are planning to launch our MotorBooster engine conditioner product during the Memorial Day weekend and, considering the rising price of fuel, we believe revenue from this new fuel saving product could easily surpass the robust results produced by WordSmart. Additionally, our PureSleep anti-snoring product, which launched in
"Over the next few weeks, we also plan to restart the advertising program for the MediPendant personal medical alarm in conjunction with our joint venture partner, Medical Alarm Concepts Holding, Inc. (OTCQB:MDHI). Recent tests showed very strong sales. We have re-cut the 120-second MediPendant commercial into a 60-second format, which we believe will produce even better results. We are also proceeding with the NutriFusion product via an upcoming retail placement in up to 300 Mannings drugstores in Hong Kong. We remain very excited about our growth prospects this year," concluded Mr. Noel.
YesDTC's growing product portfolio currently includes the NutriFusion line of easy-to-consume capsule and chewable nutraceutical supplement products; WordSmart, the knowledge and vocabulary building program sponsored by Alex Trebek of Jeopardy!; PureSleep Asia, the U.S. FDA-cleared anti-snoring dental device for the treatment of snoring, and MediPendant(TM), the only speak and listen through the pendant medical alarm system. The Company's infomercials for MediPendant and WordSmart can be seen at www.medipendant.com, and http://www.vimeo.com/16363930, respectively. More information on NutriFusion can be seen at www.nutrifusion.com
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. SMW's track record is impressive, with nearly $1.0 billion in revenues generated and a high profile list of industry awards and recognitions. Specifically, SMW campaigns include Tempur-Pedic, Guthy-Renker, Sony, 24-Hour Fitness, Rhino Records, HarperCollins and PureSleep, among many others. More information on YesDTC Holding can be found at www.yesdtc.com and additional information on Schulberg Media Works can be found at www.smw.tv.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc.
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world
Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock http://www.investorideas.com/Resources/Newsletter.asp
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp
Ronald Erickson, CEO, of Visualant Inc. (OTCBB: VSUL), Discusses the Power and
Accuracy of its Patent Pending Sensor Technology
Multiple Market Applications For Spectral Pattern Matching Technology Include Homeland
Security, Identity Theft, Environmental and Agricultural
Point Roberts, WA- March 22, 2011 – Investorideas.com, an investor research portal
specializing in sector research, including security stocks, presents a Q&A interview featuring Mr.
Ronald Erickson, CEO, President and Chairman of the Board of Visualant, Inc. (OTCBB:VSUL).
Visualant’s patent pending ‘Spectral Pattern Matching’ technology uses light to create a unique
signature for individual items and classes of items, including a recent environmental application to
identify oil in water.
Interview:
Q: Investorideas.com
Ron, according to your corporate description, your sensor technology offers the simplest, fastest
and most inexpensive means to document unique non-visible signatures from nearly any kind of
product or surface. What kind of results and feedback are you seeing with the technology as your
applications widen into new markets?
A: Ronald Erickson, CEO, President and Chairman of the Board
As we continue our work in the laboratory we are discovering some rather startling results. For
example, this past week we were able to differentiate between ten brands of vodka. I don’t
expect that to be a business focus for us. It simply illustrates the power of the Spectral Pattern
Technology to detect the unique differences that exist between substances that appear identical
to the human eye.
Q: Investorideas.com
With some of the most recent applications in conjunction with your licensed partner, Javelin LLC,
you are detecting oil in water. To what level of accuracy and to what degree can your technology
detect the oil?
A: Ronald Erickson, CEO, President and Chairman of the Board
In the laboratory test setting we have been able to detect miniscule amounts of oil or adulterates
in oil. The laboratory tests have provided evidence of an acceptable level of accuracy.
Q: Investorideas.com
From an accuracy and efficiency standpoint, who would you say your nearest competitors are in
the sensor market? And how do you compare?
A: Ronald Erickson, CEO, President and Chairman of the Board
There are any number of competitors providing competitive products in the senor market. We
believe that we have a distinct competitive advantage because of our low cost model and the
flexibility and durability of our technology.
Q: Investorideas.com
How does your technology enhance and improve overall security by adding it to current
biometrics technology?
A: Ronald Erickson, CEO, President and Chairman of the Board
The Visualant Spectral Pattern Technology adds an additional layer of authentication and
requires no added features such as an RFID chip, taggant, thread or hologram. We simply see
that color that is present.
Q: Investorideas.com
In terms of new applications, is there ongoing testing and R&D to develop new markets internally
at Visualant or do you work with partners and companies that license the technology to build this
out ?
A: Ronald Erickson, CEO, President and Chairman of the Board
We do both. We are working on a Spectral Pattern Matching Development Kit which third parties
can use to develop their own applications. We are also working on some product ideas at
Visualant which we will bring to market ourselves and in conjunction with joint venture partners.
Q: Investorideas.com
In terms of potential new partners and markets, what industry sector are you seeing the most
interest and activity in? And why do you think that is?
A. Ronald Erickson, CEO, President and Chairman of the Board
Naturally, given the focus of our TransTech subsidiary on the security and authentication
marketplace we are seeing most of our activity in that sector. It is an extremely important part of
the market.
About Visualant, Inc. (OTCBB: VSUL)
Visualant, Inc. develops low-cost, high speed, light-based security and quality control solutions
for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and
process control applications. Its patent-pending technology uses controlled illumination with
specific bands of light, to establish a unique spectral signature for both individual and classes
of items. When matched against existing databases, these spectral signatures allow precise
identification and authentication of any item or substance. This breakthrough optical sensing
and data capture technology is called Spectral Pattern Matching (SPM). SPM technology can be
miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and
can be combined in the same package as a bar-code or biometric scanner. www.visulant.net
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security
and authentication solutions to security and law enforcement markets throughout the United
States. www.ttsys.com
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visit the company profile on Investorideas.com
http://www.investorideas.com/CO/VSUL/
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector
investing, covering leading industry sectors including defense stocks, energy stocks, mining and gold
stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com
is known for its comprehensive stock directories in each sector and sector specific newswires.
Get investor alerts for VSUL:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer:
This news is paid for as part of the showcase advertising program for Visualant, Inc. (OTCBB: VSUL)
Visualant is a featured showcase company on Investorideas.com and related security portals and blogs.
The cost for this service is Two thousand five Dollars per month which has been paid by a third party. Our
sites do not make recommendations, but offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products
or securities. All information on showcase companies is taken from public documents, news, filings and
the company website and management. This site is currently compensated by featured companies, news
submissions and online advertising. Investors are reminded all investment involves risk including possible
loss of principal. Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Contact Investorideas.com
dvanzant@investorideas.com 800 665 0411
Accuracy of its Patent Pending Sensor Technology
Multiple Market Applications For Spectral Pattern Matching Technology Include Homeland
Security, Identity Theft, Environmental and Agricultural
Point Roberts, WA- March 22, 2011 – Investorideas.com, an investor research portal
specializing in sector research, including security stocks, presents a Q&A interview featuring Mr.
Ronald Erickson, CEO, President and Chairman of the Board of Visualant, Inc. (OTCBB:VSUL).
Visualant’s patent pending ‘Spectral Pattern Matching’ technology uses light to create a unique
signature for individual items and classes of items, including a recent environmental application to
identify oil in water.
Interview:
Q: Investorideas.com
Ron, according to your corporate description, your sensor technology offers the simplest, fastest
and most inexpensive means to document unique non-visible signatures from nearly any kind of
product or surface. What kind of results and feedback are you seeing with the technology as your
applications widen into new markets?
A: Ronald Erickson, CEO, President and Chairman of the Board
As we continue our work in the laboratory we are discovering some rather startling results. For
example, this past week we were able to differentiate between ten brands of vodka. I don’t
expect that to be a business focus for us. It simply illustrates the power of the Spectral Pattern
Technology to detect the unique differences that exist between substances that appear identical
to the human eye.
Q: Investorideas.com
With some of the most recent applications in conjunction with your licensed partner, Javelin LLC,
you are detecting oil in water. To what level of accuracy and to what degree can your technology
detect the oil?
A: Ronald Erickson, CEO, President and Chairman of the Board
In the laboratory test setting we have been able to detect miniscule amounts of oil or adulterates
in oil. The laboratory tests have provided evidence of an acceptable level of accuracy.
Q: Investorideas.com
From an accuracy and efficiency standpoint, who would you say your nearest competitors are in
the sensor market? And how do you compare?
A: Ronald Erickson, CEO, President and Chairman of the Board
There are any number of competitors providing competitive products in the senor market. We
believe that we have a distinct competitive advantage because of our low cost model and the
flexibility and durability of our technology.
Q: Investorideas.com
How does your technology enhance and improve overall security by adding it to current
biometrics technology?
A: Ronald Erickson, CEO, President and Chairman of the Board
The Visualant Spectral Pattern Technology adds an additional layer of authentication and
requires no added features such as an RFID chip, taggant, thread or hologram. We simply see
that color that is present.
Q: Investorideas.com
In terms of new applications, is there ongoing testing and R&D to develop new markets internally
at Visualant or do you work with partners and companies that license the technology to build this
out ?
A: Ronald Erickson, CEO, President and Chairman of the Board
We do both. We are working on a Spectral Pattern Matching Development Kit which third parties
can use to develop their own applications. We are also working on some product ideas at
Visualant which we will bring to market ourselves and in conjunction with joint venture partners.
Q: Investorideas.com
In terms of potential new partners and markets, what industry sector are you seeing the most
interest and activity in? And why do you think that is?
A. Ronald Erickson, CEO, President and Chairman of the Board
Naturally, given the focus of our TransTech subsidiary on the security and authentication
marketplace we are seeing most of our activity in that sector. It is an extremely important part of
the market.
About Visualant, Inc. (OTCBB: VSUL)
Visualant, Inc. develops low-cost, high speed, light-based security and quality control solutions
for use in homeland security, anti-counterfeiting, forgery/fraud prevention, brand protection and
process control applications. Its patent-pending technology uses controlled illumination with
specific bands of light, to establish a unique spectral signature for both individual and classes
of items. When matched against existing databases, these spectral signatures allow precise
identification and authentication of any item or substance. This breakthrough optical sensing
and data capture technology is called Spectral Pattern Matching (SPM). SPM technology can be
miniaturized and is easily integrated into a variety of hand-held or fixed mount configurations, and
can be combined in the same package as a bar-code or biometric scanner. www.visulant.net
Through its wholly owned subsidiary, TransTech Systems, Inc., the Company provides security
and authentication solutions to security and law enforcement markets throughout the United
States. www.ttsys.com
Contact:
Visualant, Inc.:
Lynn Felsinger
206 903 1351
Lynn@visualant.net
Investor Relations
Paul DeRiso
Core Consulting Group
925-465-6088
paul@coreconsultingroup.com
Visit the company profile on Investorideas.com
http://www.investorideas.com/CO/VSUL/
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector
investing, covering leading industry sectors including defense stocks, energy stocks, mining and gold
stocks, in addition to global markets including China, India, the Middle East and Australia. Investorideas.com
is known for its comprehensive stock directories in each sector and sector specific newswires.
Get investor alerts for VSUL:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer:
This news is paid for as part of the showcase advertising program for Visualant, Inc. (OTCBB: VSUL)
Visualant is a featured showcase company on Investorideas.com and related security portals and blogs.
The cost for this service is Two thousand five Dollars per month which has been paid by a third party. Our
sites do not make recommendations, but offer information portals to research news, articles, stock lists and
recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products
or securities. All information on showcase companies is taken from public documents, news, filings and
the company website and management. This site is currently compensated by featured companies, news
submissions and online advertising. Investors are reminded all investment involves risk including possible
loss of principal. Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp
Contact Investorideas.com
dvanzant@investorideas.com 800 665 0411
Monday, March 21, 2011
The Shift to Environmental Stocks; (NasdaqGS: BWEN ), .(NasdaqGS: FSLR ), (NYSE: STP ), (NYSE:
YGE )
Company Snapshots for Abtech Holdings (OTC.BB:ABHD), Clean Wind Energy Tower, Inc.
(OTCBB: CWET)
Point Roberts, WA –March 21, 2011 - Investorideas.com, a leader in cleantech stock research, reports on
morning trading for March 21. Investors continue to turn to cleantech stocks following the nuclear disaster
in Japan. In morning trading, equities, oil and gold were all up, giving investors green in all market
segments.
Green Stocks Snapshot; Morning Trading
Abtech Holdings (OTCBB:ABHD ) trading at $1.32 , up 0.05 (3.94%)
Broadwind Energy, Inc. (NasdaqGS: BWEN ) trading at $1.46, up 0.01 (0.69%) 10:31AM EDT
Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at $0.24
First Solar, Inc.(NasdaqGS: FSLR ) trading at $151.47, up 1.81 (1.21%) 10:31AM EDT
Suntech Power Holdings (NYSE: STP ) trading at $8.7, up 0.23 (2.69%) 10:31AM EDT
Yingli Green Energy Holding (NYSE: YGE ) trading at $11.81, up 0.28 (2.43%) 10:41AM EDT
Market Snapshot
Dow 12,048.22 +189.70 +1.60%
NASDAQ 2,693.38 +49.71 +1.88%
S&P 500 1,297.75 +18.55 +1.45%
10 Yr Bond(%) 3.3470% +0.0700
Oil 101.73 +0.72 +0.71%
Gold 1,433.50 +17.60 +1.24%
Research more green stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Environmental Company Snapshot
About Abtech Holdings (OTC.BB:ABHD ) and AbTech Industries
AbTech Industries, Inc. (a subsidiary of Abtech Holdings Inc.) is an environmental technologies firm
dedicated to providing innovative solutions to communities, industry and governments addressing
issues of water pollutants and contamination. Its products are based on polymer technologies capable
of removing hydrocarbons, sediment and other foreign elements from still (ponds, lakes and marinas)
or flowing water (curbside drains, pipe outflows, rivers and oceans). Smart Sponge Plus contains
an antimicrobial agent that is effective in reducing coliform bacteria found in stormwater, industrial
wastewater and municipal wastewater. AbTech's Smart Sponge technology is installed in more than
15,000 locations across America and in 8 countries worldwide.
www.abtechindustries.com
Wind Company Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc., was established
to commercialize a number of proven and validated technologies and construction systems into a single
large downdraft tower structure that use benevolent, non-toxic natural elements to generate electricity
and clean water economically by integrating and synthesizing numerous proven as well as emerging
technologies. In addition to constructing Downdraft Towers in the United States and abroad, Clean Wind
Energy, Inc. has assembled a world class team of experienced business professionals, engineers and
scientists with access to the breakthrough energy research upon which this technology is founded and
the proven ability to bring the idea to market.
Clean Wind has filed several patents that the Company believes will further enhance this potentially
revolutionary technology. The Company intends to establish partnerships at home and abroad to
propagate these systems and meet increasing global demand for clean water and electricity.
www.cleanwindenergytower.com
Visit the showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
Recent News:
Clean Wind Energy Tower, Inc. (OTCBB: CWET) Files Unique Hydraulic System Patent
Maximizing the Capture and Use of Available Wind Tunnel Energy
ANNAPOLIS, MD - March 7, 2011 (InvestorIdeas.com Newswire) - Clean Wind Energy Tower, Inc.
(OTCBB: CWET) announced that the Company had filed with the United States Patent & Trademark
Office "A Petition to Make Special Under Accelerated Examination Program," a patent application titled
Efficient Energy Conversion Devices & Methods. The application covers specific aspects of deploying
multiple turbines in a wind tunnel coupled to a novel hydraulic system capable of maintaining high
efficiency hydraulic to electric conversion under a wide variance of wind speeds. The ultimate goal is
to maximize the capture and utilization of all available wind energy in any given wind tunnel, as well as
providing a consistency of power output during deviations in wind speed.
Full news: http://www.investorideas.com/CO/CWE/news/2011/03071.asp
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
stocks and has become a global go-to destination for investors researching the cleantech sector, with
stock directories, company news, commentary from experts, research reports and industry resources and
links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on (OTCBB: CWET)
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET)
advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one
thousand five hundred per month, 100,000 144 shares ) to be showcased as a renewable energy stock within its
hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer
or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees
as to the accuracy of information presented. All Information relating to featured companies is sourced from public
documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
YGE )
Company Snapshots for Abtech Holdings (OTC.BB:ABHD), Clean Wind Energy Tower, Inc.
(OTCBB: CWET)
Point Roberts, WA –March 21, 2011 - Investorideas.com, a leader in cleantech stock research, reports on
morning trading for March 21. Investors continue to turn to cleantech stocks following the nuclear disaster
in Japan. In morning trading, equities, oil and gold were all up, giving investors green in all market
segments.
Green Stocks Snapshot; Morning Trading
Abtech Holdings (OTCBB:ABHD ) trading at $1.32 , up 0.05 (3.94%)
Broadwind Energy, Inc. (NasdaqGS: BWEN ) trading at $1.46, up 0.01 (0.69%) 10:31AM EDT
Clean Wind Energy Tower, Inc. (OTCBB: CWET) trading at $0.24
First Solar, Inc.(NasdaqGS: FSLR ) trading at $151.47, up 1.81 (1.21%) 10:31AM EDT
Suntech Power Holdings (NYSE: STP ) trading at $8.7, up 0.23 (2.69%) 10:31AM EDT
Yingli Green Energy Holding (NYSE: YGE ) trading at $11.81, up 0.28 (2.43%) 10:41AM EDT
Market Snapshot
Dow 12,048.22 +189.70 +1.60%
NASDAQ 2,693.38 +49.71 +1.88%
S&P 500 1,297.75 +18.55 +1.45%
10 Yr Bond(%) 3.3470% +0.0700
Oil 101.73 +0.72 +0.71%
Gold 1,433.50 +17.60 +1.24%
Research more green stocks with the renewable energy stocks directory:
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp
Environmental Company Snapshot
About Abtech Holdings (OTC.BB:ABHD ) and AbTech Industries
AbTech Industries, Inc. (a subsidiary of Abtech Holdings Inc.) is an environmental technologies firm
dedicated to providing innovative solutions to communities, industry and governments addressing
issues of water pollutants and contamination. Its products are based on polymer technologies capable
of removing hydrocarbons, sediment and other foreign elements from still (ponds, lakes and marinas)
or flowing water (curbside drains, pipe outflows, rivers and oceans). Smart Sponge Plus contains
an antimicrobial agent that is effective in reducing coliform bacteria found in stormwater, industrial
wastewater and municipal wastewater. AbTech's Smart Sponge technology is installed in more than
15,000 locations across America and in 8 countries worldwide.
www.abtechindustries.com
Wind Company Snapshot
Clean Wind Energy Tower, Inc. (OTCBB: CWET)
Clean Wind Energy, Inc., a wholly owned subsidiary of Clean Wind Energy Tower, Inc., was established
to commercialize a number of proven and validated technologies and construction systems into a single
large downdraft tower structure that use benevolent, non-toxic natural elements to generate electricity
and clean water economically by integrating and synthesizing numerous proven as well as emerging
technologies. In addition to constructing Downdraft Towers in the United States and abroad, Clean Wind
Energy, Inc. has assembled a world class team of experienced business professionals, engineers and
scientists with access to the breakthrough energy research upon which this technology is founded and
the proven ability to bring the idea to market.
Clean Wind has filed several patents that the Company believes will further enhance this potentially
revolutionary technology. The Company intends to establish partnerships at home and abroad to
propagate these systems and meet increasing global demand for clean water and electricity.
www.cleanwindenergytower.com
Visit the showcase page at Investorideas.com: http://www.investorideas.com/CO/CWE/
Recent News:
Clean Wind Energy Tower, Inc. (OTCBB: CWET) Files Unique Hydraulic System Patent
Maximizing the Capture and Use of Available Wind Tunnel Energy
ANNAPOLIS, MD - March 7, 2011 (InvestorIdeas.com Newswire) - Clean Wind Energy Tower, Inc.
(OTCBB: CWET) announced that the Company had filed with the United States Patent & Trademark
Office "A Petition to Make Special Under Accelerated Examination Program," a patent application titled
Efficient Energy Conversion Devices & Methods. The application covers specific aspects of deploying
multiple turbines in a wind tunnel coupled to a novel hydraulic system capable of maintaining high
efficiency hydraulic to electric conversion under a wide variance of wind speeds. The ultimate goal is
to maximize the capture and utilization of all available wind energy in any given wind tunnel, as well as
providing a consistency of power output during deviations in wind speed.
Full news: http://www.investorideas.com/CO/CWE/news/2011/03071.asp
About Investorideas.com and our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy
stocks and has become a global go-to destination for investors researching the cleantech sector, with
stock directories, company news, commentary from experts, research reports and industry resources and
links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Sign up at Investor Ideas for free investor alerts including news on (OTCBB: CWET)
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET)
advertising program with Investorideas.com. Clean Wind Energy, Inc. compensates investorideas.com (one
thousand five hundred per month, 100,000 144 shares ) to be showcased as a renewable energy stock within its
hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer
or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees
as to the accuracy of information presented. All Information relating to featured companies is sourced from public
documents and/ or the company and its management and is not the opinion of Investorideas.com.
Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com
Friday, March 18, 2011
Agriculture Stocks, Cloud Computing Stocks and Social Networking Stocks
added to Directories for Investors at Investorideas.com
Sectors Include energy stocks mining, biotech stocks, renewable energy,
water
POINT ROBERTS, Wash., March 18, 2011 - www.InvestorIdeas.com, a global
investor research portal, specializing in sector research, reports
additions to the Investor Ideas member content include the agriculture stocks
directory in addition to the tech stocks directory featuring cloud computing and
social media stocks.
Investorideas.com covers leading sectors for investors with research tools
including stock directories, news, articles and featured stocks within each sector.
Sectors covered include oil and gas, natural gas, defense, biotech, mining,
nanotech, water, tech, agriculture and other high profile sectors.
The agriculture stocks directory has been one of the most visited pages on the
site for several months as global food concerns and prices rise.
Preview the agriculture stocks directory: http://www.investorideas.com/MSS/
Arg_Stock_List.asp
Investor Ideas membership currently features eleven stock directories, including
one of the largest green and renewable energy stocks directory online, featuring
over 1200 green publicly traded companies .
Visit the Investor Ideas membership page to learn more at: http://
www.investorideas.com/membership/
Additional stock directories at Investorideas.com for investors:
Renewable Energy Stocks Directory - Global Green and Renewable Energy
Stocks Directory in PDF format includes over 1200 stocks on the TSX, TSX
Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global
Stock Exchanges . The directory features hyperlinks to stocks symbol(s),
company’s URL and company’s description. The directory includes info and links
on Alternative Energy Funds, Biogas and Ethanol Stocks, Energy Efficiency
Stocks, Flywheel Stocks, Fuel Cell Stocks, Geothermal Stocks, Hydrogen
Production, Micro Turbine Stocks, Solar Stocks, Smart Grid Stocks, Green
Transportation, Wind Power and Wind Energy Stocks and Green Infrastructure
Stocks. For investors following green stocks, this is the most comprehensive
global stock directory online.
Mining and Gold Stocks Directory - Global Mining and Gold Stocks Directory
in PDF format lists over 1100 publicly traded mining companies. Mining and
metals investors can research gold and mining stocks with the mining stocks
directory, featuring Gold Stocks, Silver Stocks, Uranium Stocks, Copper Stocks,
Zinc Stocks and Precious Metals TSX, TSX Venture, OTC, NASDAQ, AMEX,
NYSE, ASX, AIM and other leading Stock Exchanges. directory features
hyperlinks to stocks symbol(s), company’s URL and company’s description.
Oil and Gas Stocks Directory - Global Oil and Gas Stocks Directory of Publicly
traded oil and gas stocks listed on the TSX, TSX Venture, OTC, NASDAQ,
AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The
comprehensive directory gives investors a full range and choice of micro cap
to large cap stocks in the energy sector. The directory in PDF format, features
hyperlinks to over 600 stocks symbol(s), company's URL and company's
description.
Coal Stocks Directory - Global Directory of Publicly traded Coal stocks listed
on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM, China
and other leading global Stock Exchanges . The comprehensive directory gives
investors a full range and choice of micro cap to large cap stocks in the coal
sector, including clean coal and coking coal stocks. The directory in PDF format,
features hyperlinks to coal stocks symbol(s), company's URL and company's
description.
Defense Stocks Directory - Global Defense and Homeland Security Stocks
Directory features publicly traded defense stocks listed on the TSX, TSX
Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global
Stock Exchanges. The directory, in PDF format, includes Homeland Security
Stocks, Aerospace and Defense Stocks, Biodefense Stocks, Security Stocks,
Energy Security Stocks and Infrastructure Stocks with hyperlinks to stocks
symbol(s), company's URL and company's description. For defense stocks
followers, this is one of the most comprehensive global stock directories available
to investors.
Water Stocks Directory - Global Water Stocks Directory of publicly traded water
stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The stock directory features
water stocks ranging from desalination companies to bottled water stocks, to
infrastructure, water treatment and technology as well as other sub sectors. The
directory in PDF format, features hyperlinks to stocks symbol(s), company's URL
and company's description. For investors following water stocks this is one of the
most comprehensive directories in the sector available.
Environment Stocks Directory - Global Green Stocks Directory of Publicly
traded Environmental Stocks listed on the TSX, TSX Venture, OTC, NASDAQ,
AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The
directory in PDF format, features hyperlinks to stocks symbol(s), company's URL
and company's description.
Fuel Cell Stocks Directory - Global Directory of Publicly traded Fuel Cell
Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The directory includes small
cap, micro cap as well as large cap NYSE listed stocks for review. For green
investors looking for opportunities in the fuel cell sector, the comprehensive
global directory in PDF format provides a great research tool with hyperlinks to
stocks symbol(s), company's URL and company's description.
Biotech Stocks Directory - Global Directory of Publicly Traded Biotech,Pharma
and Life Sciences Stocks ,on the TSX, TSX Venture, OTC, NASDAQ, AMEX,
NYSE, ASX, AIM and other leading global Stock Exchanges . The directory
covers all sub sectors of biotech including nanotech, biodefense and stem cell
stocks. The directory includes small cap, micro cap as well as large cap NYSE
listed stocks for investors The comprehensive global directory in PDF format
provides a great research tool for biotechnology investors with hyperlinks to
stocks symbol(s), company's URL and company's description.
Natural Gas Stocks Directory - Global Directory of Publicly traded Natural Gas
Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The directory includes small cap,
micro cap as well as large cap NYSE listed stocks for review. Natural gas stocks
included range from LNG, Coal Bed Methane to exploration and producers in
the sector. The directory in PDF format, features hyperlinks to stocks symbol(s),
company's URL and company's description.
Nanotechnology Stocks Directory - Investorideas.com global stock directory
of publicly traded nanotech stocks on the TSX, TSX Venture, OTC, NASDAQ,
AMEX, NYSE, ASX, AIM, Hong Kong and China and other leading Stock
Exchanges. Directory includes nanotech- biotech companies, nanotech water
and renewable energy companies and more. Directory features company
description, stock symbol and hyperlink to recent quote and info, link to website
and more.
Visit the Investor Ideas membership page to learn more at: http://
www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading
sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector
investing content.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as
an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we
offer no guarantees as to the accuracy of information presented. All Information relating to featured
companies is sourced from public documents and/ or the company and is not the opinion of our web sites.
This site is currently compensated by featured companies, news submissions and online advertising.
www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue
partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source – Investorideas.com
added to Directories for Investors at Investorideas.com
Sectors Include energy stocks mining, biotech stocks, renewable energy,
water
POINT ROBERTS, Wash., March 18, 2011 - www.InvestorIdeas.com, a global
investor research portal, specializing in sector research, reports
additions to the Investor Ideas member content include the agriculture stocks
directory in addition to the tech stocks directory featuring cloud computing and
social media stocks.
Investorideas.com covers leading sectors for investors with research tools
including stock directories, news, articles and featured stocks within each sector.
Sectors covered include oil and gas, natural gas, defense, biotech, mining,
nanotech, water, tech, agriculture and other high profile sectors.
The agriculture stocks directory has been one of the most visited pages on the
site for several months as global food concerns and prices rise.
Preview the agriculture stocks directory: http://www.investorideas.com/MSS/
Arg_Stock_List.asp
Investor Ideas membership currently features eleven stock directories, including
one of the largest green and renewable energy stocks directory online, featuring
over 1200 green publicly traded companies .
Visit the Investor Ideas membership page to learn more at: http://
www.investorideas.com/membership/
Additional stock directories at Investorideas.com for investors:
Renewable Energy Stocks Directory - Global Green and Renewable Energy
Stocks Directory in PDF format includes over 1200 stocks on the TSX, TSX
Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global
Stock Exchanges . The directory features hyperlinks to stocks symbol(s),
company’s URL and company’s description. The directory includes info and links
on Alternative Energy Funds, Biogas and Ethanol Stocks, Energy Efficiency
Stocks, Flywheel Stocks, Fuel Cell Stocks, Geothermal Stocks, Hydrogen
Production, Micro Turbine Stocks, Solar Stocks, Smart Grid Stocks, Green
Transportation, Wind Power and Wind Energy Stocks and Green Infrastructure
Stocks. For investors following green stocks, this is the most comprehensive
global stock directory online.
Mining and Gold Stocks Directory - Global Mining and Gold Stocks Directory
in PDF format lists over 1100 publicly traded mining companies. Mining and
metals investors can research gold and mining stocks with the mining stocks
directory, featuring Gold Stocks, Silver Stocks, Uranium Stocks, Copper Stocks,
Zinc Stocks and Precious Metals TSX, TSX Venture, OTC, NASDAQ, AMEX,
NYSE, ASX, AIM and other leading Stock Exchanges. directory features
hyperlinks to stocks symbol(s), company’s URL and company’s description.
Oil and Gas Stocks Directory - Global Oil and Gas Stocks Directory of Publicly
traded oil and gas stocks listed on the TSX, TSX Venture, OTC, NASDAQ,
AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The
comprehensive directory gives investors a full range and choice of micro cap
to large cap stocks in the energy sector. The directory in PDF format, features
hyperlinks to over 600 stocks symbol(s), company's URL and company's
description.
Coal Stocks Directory - Global Directory of Publicly traded Coal stocks listed
on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM, China
and other leading global Stock Exchanges . The comprehensive directory gives
investors a full range and choice of micro cap to large cap stocks in the coal
sector, including clean coal and coking coal stocks. The directory in PDF format,
features hyperlinks to coal stocks symbol(s), company's URL and company's
description.
Defense Stocks Directory - Global Defense and Homeland Security Stocks
Directory features publicly traded defense stocks listed on the TSX, TSX
Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global
Stock Exchanges. The directory, in PDF format, includes Homeland Security
Stocks, Aerospace and Defense Stocks, Biodefense Stocks, Security Stocks,
Energy Security Stocks and Infrastructure Stocks with hyperlinks to stocks
symbol(s), company's URL and company's description. For defense stocks
followers, this is one of the most comprehensive global stock directories available
to investors.
Water Stocks Directory - Global Water Stocks Directory of publicly traded water
stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The stock directory features
water stocks ranging from desalination companies to bottled water stocks, to
infrastructure, water treatment and technology as well as other sub sectors. The
directory in PDF format, features hyperlinks to stocks symbol(s), company's URL
and company's description. For investors following water stocks this is one of the
most comprehensive directories in the sector available.
Environment Stocks Directory - Global Green Stocks Directory of Publicly
traded Environmental Stocks listed on the TSX, TSX Venture, OTC, NASDAQ,
AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The
directory in PDF format, features hyperlinks to stocks symbol(s), company's URL
and company's description.
Fuel Cell Stocks Directory - Global Directory of Publicly traded Fuel Cell
Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The directory includes small
cap, micro cap as well as large cap NYSE listed stocks for review. For green
investors looking for opportunities in the fuel cell sector, the comprehensive
global directory in PDF format provides a great research tool with hyperlinks to
stocks symbol(s), company's URL and company's description.
Biotech Stocks Directory - Global Directory of Publicly Traded Biotech,Pharma
and Life Sciences Stocks ,on the TSX, TSX Venture, OTC, NASDAQ, AMEX,
NYSE, ASX, AIM and other leading global Stock Exchanges . The directory
covers all sub sectors of biotech including nanotech, biodefense and stem cell
stocks. The directory includes small cap, micro cap as well as large cap NYSE
listed stocks for investors The comprehensive global directory in PDF format
provides a great research tool for biotechnology investors with hyperlinks to
stocks symbol(s), company's URL and company's description.
Natural Gas Stocks Directory - Global Directory of Publicly traded Natural Gas
Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX,
AIM and other leading global Stock Exchanges. The directory includes small cap,
micro cap as well as large cap NYSE listed stocks for review. Natural gas stocks
included range from LNG, Coal Bed Methane to exploration and producers in
the sector. The directory in PDF format, features hyperlinks to stocks symbol(s),
company's URL and company's description.
Nanotechnology Stocks Directory - Investorideas.com global stock directory
of publicly traded nanotech stocks on the TSX, TSX Venture, OTC, NASDAQ,
AMEX, NYSE, ASX, AIM, Hong Kong and China and other leading Stock
Exchanges. Directory includes nanotech- biotech companies, nanotech water
and renewable energy companies and more. Directory features company
description, stock symbol and hyperlink to recent quote and info, link to website
and more.
Visit the Investor Ideas membership page to learn more at: http://
www.investorideas.com/membership/
Sign up for the free investor news letter and get stock alerts in leading
sectors! http://www.investorideas.com/Resources/Newsletter.asp
About InvestorIdeas.com:
Investor Ideas is a global financial media online destination specialized in sector
investing content.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as
an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we
offer no guarantees as to the accuracy of information presented. All Information relating to featured
companies is sourced from public documents and/ or the company and is not the opinion of our web sites.
This site is currently compensated by featured companies, news submissions and online advertising.
www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue
partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source – Investorideas.com
Biotech Sector Snapshot HIV Drug Development; (OTCBB: AEMD), (NYSE: BMY), (Nasdaq: GILD), (NYSE: PFE)
Industry Warns of Drug Resistance Potential for HIV Drugs
Point Roberts, WA - March 18, 2011- Investorideas.com releases an industry snapshot on HIV- AIDS drug makers and recent data that suggests the HIV virus has developed drug resistance and that drug industry is not acting fast enough to get new drugs into the pipeline to combat the potential threats.
Company snapshots include Gilead Sciences, Inc. (NasdaqGS: GILD), the largest player in HIV/AIDS products and medical technology companyAethlon Medical (OTCBB: AEMD).
Aethlon Medical (OTCBB: AEMD) is betting that its medical technology,
Hemopurifier® may offer solutions. Human studies have documented the ability of the Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.
"In the absence of a cure for AIDS, the drug industry responded with antiviral regimens that have allowed HIV-infected individuals the ability to effectively manage their disease," stated Jim Joyce, CEO at Aethlon Medical. "However, with a shrinking drug pipeline, the big question now is who is going to help these individuals at the point they become resistant to drug regimens?"
"Much like dialysis has extended the lives of those with kidney failure, we have created a therapeutic filtration device known as the Hemopurifier® that provides a device mechanism to address all circulating HIV strains, including those resistant to HIV drug therapies. Additionally, the device fills the unmet medical need of clearing immunosuppressive toxins that are shed by the virus to deplete immune cells, which is the hallmark of AIDS," concluded Joyce.
In the absence of drug therapy, Aethlon recently demonstrated immune function improvement and a greater than 90% viral load reduction in an AIDS patient as the result of 12 treatments administered over the course of one month.
UNAIDS recently reported in a press release, "Millions of people in developing countries now depend on a steady supply of affordable first-line treatment for HIV. If their treatment is interrupted, which can lead to drug resistance, these patients will have to switch to a second-line regimen. That can be at least six times more expensive than the first-line regimen," said Dr Gottfried Hirnschall, Director of WHO's HIV/AIDS Department.
A recent article on Bloomberg.com entitled , HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success" reports "Without a steady stream of new medicines to attack the virus in different ways, drug resistance will develop, leaving more patients without a viable treatment, said Scott Hammer, a professor of medicine at Columbia University in New York.
"If we are complacent, resistance will start to spread against the key components of our therapies," Hammer said in an interview. "We need to be ready for that because we won't be able to catch up after it happens."
Link to full story: http://www.bloomberg.com/news/2011-03-14/gilead-s-high-bar-for-aids-drugs-means-new-development-withers.html
At the end of 2009, nearly 15 million people were estimated to be in need of antiretroviral treatment for HIV and 5.2 million people had access to the life-saving therapy. Source: UNAIDS
UNDP,WHO.
Biotech/Pharma Sector Snapshot
Products HIV/AIDS
Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) is the first and only once-daily single tablet regimen for the treatment of HIV infection in adults. It is intended for use as a stand-alone therapy, or in combination with other antiretrovirals, and combines Gilead's Truvada® (emtricitabine and tenofovir disoproxil fumarate) with Sustiva® (efavirenz), manufactured by Bristol-Myers Squibb. ( U.S. approval, 2006; E.U. approval, 2007.)
Emtriva® (emtricitabine) is a once-daily oral nucleoside reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents for the treatment of HIV infection in adults. Emtriva is also available as an oral solution for use in pediatric patients. ( U.S. and E.U. approval, 2003.)
Truvada® (emtricitabine and tenofovir disoproxil fumarate) is a fixed-dose once-daily combination pill containing Viread® and Emtriva®. It is used in combination with other antiretroviral agents for the treatment of HIV infection in adults. ( U.S. approval, 2004; E.U. approval, 2005.)
Viread® (tenofovir disoproxil fumarate) is a once-daily oral nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV infection in adults and adolescents in combination with other antiretroviral agents. ( U.S. approval, 2001; E.U. approval, 2002.) Viread® was also approved in 2008 as a treatment for chronic hepatitis B in adults. ( U.S. and EU approval, 2008.)
Company Snapshot
About Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings .
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Industry Warns of Drug Resistance Potential for HIV Drugs
Point Roberts, WA - March 18, 2011- Investorideas.com releases an industry snapshot on HIV- AIDS drug makers and recent data that suggests the HIV virus has developed drug resistance and that drug industry is not acting fast enough to get new drugs into the pipeline to combat the potential threats.
Company snapshots include Gilead Sciences, Inc. (NasdaqGS: GILD), the largest player in HIV/AIDS products and medical technology companyAethlon Medical (OTCBB: AEMD).
Aethlon Medical (OTCBB: AEMD) is betting that its medical technology,
Hemopurifier® may offer solutions. Human studies have documented the ability of the Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.
"In the absence of a cure for AIDS, the drug industry responded with antiviral regimens that have allowed HIV-infected individuals the ability to effectively manage their disease," stated Jim Joyce, CEO at Aethlon Medical. "However, with a shrinking drug pipeline, the big question now is who is going to help these individuals at the point they become resistant to drug regimens?"
"Much like dialysis has extended the lives of those with kidney failure, we have created a therapeutic filtration device known as the Hemopurifier® that provides a device mechanism to address all circulating HIV strains, including those resistant to HIV drug therapies. Additionally, the device fills the unmet medical need of clearing immunosuppressive toxins that are shed by the virus to deplete immune cells, which is the hallmark of AIDS," concluded Joyce.
In the absence of drug therapy, Aethlon recently demonstrated immune function improvement and a greater than 90% viral load reduction in an AIDS patient as the result of 12 treatments administered over the course of one month.
UNAIDS recently reported in a press release, "Millions of people in developing countries now depend on a steady supply of affordable first-line treatment for HIV. If their treatment is interrupted, which can lead to drug resistance, these patients will have to switch to a second-line regimen. That can be at least six times more expensive than the first-line regimen," said Dr Gottfried Hirnschall, Director of WHO's HIV/AIDS Department.
A recent article on Bloomberg.com entitled , HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success" reports "Without a steady stream of new medicines to attack the virus in different ways, drug resistance will develop, leaving more patients without a viable treatment, said Scott Hammer, a professor of medicine at Columbia University in New York.
"If we are complacent, resistance will start to spread against the key components of our therapies," Hammer said in an interview. "We need to be ready for that because we won't be able to catch up after it happens."
Link to full story: http://www.bloomberg.com/news/2011-03-14/gilead-s-high-bar-for-aids-drugs-means-new-development-withers.html
At the end of 2009, nearly 15 million people were estimated to be in need of antiretroviral treatment for HIV and 5.2 million people had access to the life-saving therapy. Source: UNAIDS
UNDP,WHO.
Biotech/Pharma Sector Snapshot
- Aethlon Medical (OTCBB: AEMD) trading at $0.14
- Bristol-Myers Squibb Company (NYSE: BMY) trading at $25.77 0.34 (1.34%) 10:58AM EDT
- Gilead Sciences, Inc. (NasdaqGS: GILD) trading at $40.64, up 0.33 (0.82%) 10:59AM EDT
- GlaxoSmithKline (NYSE: GSK) trading at $ 37.33, down 0.01 (0.03%) 11:06AM EDT
- Johnson & Johnson (NYSE: JNJ) trading at $58.5, up 0.43 (0.74%) 11:08AM EDT
- Pfizer, Inc. (NYSE: PFE) trading at $ 20.06, up 0.18 (0.88%) 11:09AM EDT
Products HIV/AIDS
Atripla® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) is the first and only once-daily single tablet regimen for the treatment of HIV infection in adults. It is intended for use as a stand-alone therapy, or in combination with other antiretrovirals, and combines Gilead's Truvada® (emtricitabine and tenofovir disoproxil fumarate) with Sustiva® (efavirenz), manufactured by Bristol-Myers Squibb. ( U.S. approval, 2006; E.U. approval, 2007.)
Emtriva® (emtricitabine) is a once-daily oral nucleoside reverse transcriptase inhibitor (NRTI) used in combination with other antiretroviral agents for the treatment of HIV infection in adults. Emtriva is also available as an oral solution for use in pediatric patients. ( U.S. and E.U. approval, 2003.)
Truvada® (emtricitabine and tenofovir disoproxil fumarate) is a fixed-dose once-daily combination pill containing Viread® and Emtriva®. It is used in combination with other antiretroviral agents for the treatment of HIV infection in adults. ( U.S. approval, 2004; E.U. approval, 2005.)
Viread® (tenofovir disoproxil fumarate) is a once-daily oral nucleotide reverse transcriptase inhibitor (NtRTI) for the treatment of HIV infection in adults and adolescents in combination with other antiretroviral agents. ( U.S. approval, 2001; E.U. approval, 2002.) Viread® was also approved in 2008 as a treatment for chronic hepatitis B in adults. ( U.S. and EU approval, 2008.)
Company Snapshot
About Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings .
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Effective March 15, 2011
Thursday, March 17, 2011
Biotech/Pharma Sector Close-Up; (OTCBB: AEMD), (NYSE: BMY), (Nasdaq: GILD), (NYSE: PFE)
Point Roberts, WA - March 18, 2011 - Investorideas.com, a leader in investor sector research including biotech and pharma stocks releases a sector snapshot on the HIV- AIDS drug makers and recent data that suggests the HIV virus may be following the path of bacteria that has developed drug resistance and that drug industry is not acting fast enough to get new drugs into the pipeline to combat the potential threats.
In that light, small player Aethlon Medical (OTCBB: AEMD) is betting that its medical technology,
Hemopurifier® may offer solutions. Human studies have documented the ability of the Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.
"In the absence of a cure for AIDS, the drug industry responded with antiviral regimens that have allowed HIV-infected individuals the ability to effectively manage their disease," stated Jim Joyce, CEO at Aethlon Medical. "However, with a shrinking drug pipeline, the big question now is who is going to help these individuals at the point they become resistant to drug regimens?"
"Much like dialysis has extended the lives of those with kidney failure, we have created a therapeutic filtration device known as the Hemopurifier® that provides a device mechanism to address all circulating HIV strains, including those resistant to HIV drug therapies. Additionally, the device fills the unmet medical need of clearing immunosuppressive toxins that are shed by the virus to deplete immune cells, which is the hallmark of AIDS," concluded Joyce.
In the absence of drug therapy, Aethlon recently demonstrated immune function improvement and a greater than 90% viral load reduction in an AIDS patient as the result of 12 treatments administered over the course of one month.
UNAIDS recently reported in a press release, "Millions of people in developing countries now depend on a steady supply of affordable first-line treatment for HIV. If their treatment is interrupted, which can lead to drug resistance, these patients will have to switch to a second-line regimen. That can be at least six times more expensive than the first-line regimen," said Dr Gottfried Hirnschall, Director of WHO's HIV/AIDS Department.
A recent article on Bloomberg.com entitled, HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success" reports "Without a steady stream of new medicines to attack the virus in different ways, drug resistance will develop, leaving more patients without a viable treatment, said Scott Hammer, a professor of medicine at Columbia University in New York.
"If we are complacent, resistance will start to spread against the key components of our therapies," Hammer said in an interview. "We need to be ready for that because we won't be able to catch up after it happens."
Link to full story: http://www.bloomberg.com/news/2011-03-14/gilead-s-high-bar-for-aids-drugs-means-new-development-withers.html
At the end of 2009, nearly 15 million people were estimated to be in need of antiretroviral treatment for HIV and 5.2 million people had access to the life-saving therapy. Source: UNAIDS
UNDP,WHO.
Biotech/Pharma Sector Snapshot
About Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings .
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Point Roberts, WA - March 18, 2011 - Investorideas.com, a leader in investor sector research including biotech and pharma stocks releases a sector snapshot on the HIV- AIDS drug makers and recent data that suggests the HIV virus may be following the path of bacteria that has developed drug resistance and that drug industry is not acting fast enough to get new drugs into the pipeline to combat the potential threats.
In that light, small player Aethlon Medical (OTCBB: AEMD) is betting that its medical technology,
Hemopurifier® may offer solutions. Human studies have documented the ability of the Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.
"In the absence of a cure for AIDS, the drug industry responded with antiviral regimens that have allowed HIV-infected individuals the ability to effectively manage their disease," stated Jim Joyce, CEO at Aethlon Medical. "However, with a shrinking drug pipeline, the big question now is who is going to help these individuals at the point they become resistant to drug regimens?"
"Much like dialysis has extended the lives of those with kidney failure, we have created a therapeutic filtration device known as the Hemopurifier® that provides a device mechanism to address all circulating HIV strains, including those resistant to HIV drug therapies. Additionally, the device fills the unmet medical need of clearing immunosuppressive toxins that are shed by the virus to deplete immune cells, which is the hallmark of AIDS," concluded Joyce.
In the absence of drug therapy, Aethlon recently demonstrated immune function improvement and a greater than 90% viral load reduction in an AIDS patient as the result of 12 treatments administered over the course of one month.
UNAIDS recently reported in a press release, "Millions of people in developing countries now depend on a steady supply of affordable first-line treatment for HIV. If their treatment is interrupted, which can lead to drug resistance, these patients will have to switch to a second-line regimen. That can be at least six times more expensive than the first-line regimen," said Dr Gottfried Hirnschall, Director of WHO's HIV/AIDS Department.
A recent article on Bloomberg.com entitled, HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success" reports "Without a steady stream of new medicines to attack the virus in different ways, drug resistance will develop, leaving more patients without a viable treatment, said Scott Hammer, a professor of medicine at Columbia University in New York.
"If we are complacent, resistance will start to spread against the key components of our therapies," Hammer said in an interview. "We need to be ready for that because we won't be able to catch up after it happens."
Link to full story: http://www.bloomberg.com/news/2011-03-14/gilead-s-high-bar-for-aids-drugs-means-new-development-withers.html
At the end of 2009, nearly 15 million people were estimated to be in need of antiretroviral treatment for HIV and 5.2 million people had access to the life-saving therapy. Source: UNAIDS
UNDP,WHO.
Biotech/Pharma Sector Snapshot
- Aethlon Medical (OTCBB: AEMD) trading at $0.15, up 0.01 (5.71%)
- Bristol-Myers Squibb Company (NYSE: BMY ) trading at $25.37, up 0.40 (1.60%) 1:02PM EDT
- Gilead Sciences, Inc. (NasdaqGS: GILD ) trading at $40.17, up 0.33 (0.83%) 1:03PM EDT
- GlaxoSmithKline (NYSE: GSK ) trading at $40.18, up 0.34 (0.85%) 1:04PM EDT
- Johnson & Johnson (NYSE: JNJ ) trading at $58.17, up 0.51 (0.88%) 1:05PM EDT
- Pfizer, Inc.(NYSE: PFE ) trading at $19.70, up 0.40 (2.07%) 1:05PM EDT
- Dow 11,755.82 +142.52 +1.23%
- Nasdaq 2,651.69 +34.87 +1.33%
- S&P 500 1,274.35 +17.47 +1.39%
- 10 Yr Bond(%) 3.2740% +0.0620
- Oil 100.84 +2.86 +2.92%
- Gold 1,396.00 0.00 0.00%
About Aethlon Medical ( OTCBB:AEMD)
At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.
Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.
Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs. However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union. In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.
3.Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.
The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.
In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings .
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks with its portal BiotechIndustryStocks.com.
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
Visit the showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD
Get added to the company's news alerts:
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com
Electric Car Stocks Snapshot; (NasdaqGM: AONE), (NASDAQ: HEV), (OTCBB: EVCA)), (NYSE: NRG), (NASDAQ: TSLA)
Point Roberts, WA - March 18, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a leader in cleantech investor research, reports on electric car stocks and battery stocks trading for March 18th. A recent report by IDTechEx calls the hybrid and EV cars the new gold rush 2011- 2021.
With higher oil prices, the sector has had some ups and downs, with the overall market volatility. Long term- the green car enthusiasts are bullish. Just like the cars, most of the stocks in the sector are trading up and in the green this morning.
"Hybrid and Pure Electric Cars 2011-2021" and "Car Traction Batteries - The New Gold Rush 2011-2021"
Good volume growth but greater value growth The 30.6 million EVs sold in 2011 will rise to 51.3 million in 2021 but the value of the market will grow by far more because larger and more expensive vehicles are now rapidly adopting the technology. Motorcycles, military vehicles, buses and earthmovers are among them. Hybrids will rise from about 50% to about 60% of the value market through the decade. In ten years from now, a far higher percentage of the global output of light industrial vehicles, commercial vehicles and cars will be EVs. The new report gives the detail, forecasting numbers, unit value and total market value for each applicational sector with many original tables giving subsets of the data and a large number of profiles of current and planned activities of the participants. Some EV sectors were hit by the global financial meltdown but are recovering. Many sectors now benefit from the tsunami wave of government benefits, technical innovations and new models becoming available. We evaluate these aspects and the market drivers, including what users really need. Battery, motor and other technology is explained and forecasted as well. This report "Electric Vehicles 2011-2021" is a sister report to IDTechEx reports about the two most important subsectors of the EV business - "Hybrid and Pure Electric Cars 2011-2021" and "Car Traction Batteries - The New Gold Rush 2011-2021".
For more information visit http://www.researchandmarkets.com/research/a7c011/electric_vehicles
EV Sector Snapshot Morning Trading March 18th
EVCARCO (OTC.BB: EVCA) to Showcase Latest Alternative Energy Units at Ft. Worth Auto Show
CNG Units to Be Displayed for Commercial Customers
Full news;http://www.investorideas.com/CO/EVCA/news/2011/03171.asp
Company Snapshots
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
NRG Energy, Inc., a Fortune 500 and S&P 500 Index company, owns and operates one of the country's largest and most diverse power generation portfolios. Headquartered in Princeton, NJ, the Company's power plants provide nearly 26,000 megawatts of generation capacity—enough to supply more than 20 million homes. NRG's retail businesses, Reliant Energy and Green Mountain Energy Company, combined serve more than 1.8 million residential, business, commercial and industrial customers. With investments in solar, wind and nuclear power, as well as electric vehicle infrastructure, NRG is working to help America's transition to a clean energy economy.
NRG Energy is a founding member of the Electrification Coalition, a nonpartisan, not-for-profit group of business leaders committed to promoting policies and actions that facilitate the deployment of electric vehicles on a mass scale. More information is available at www.nrgenergy.com.
About eVgo
eVgo is the nation's first privately funded, comprehensive electric vehicle ecosystem. The eVgo network gives EV owners new freedom and range confidence via home charging and fast-charging stations conveniently located at major retailers, employers and along highways across eVgo cities. eVgo allows EV owners to avoid paying large up-front costs for a home charger and provides unlimited use remote charging—all for one low monthly fee. To find out more, or to join the eVgo network, visit www.evgonetwork.com.
More News:
Find electric vehicle charging stations on Google Maps
Wednesday, March 9, 2011 at 9:30 AM
[Cross-posted from the Google.org Blog]
http://google-latlong.blogspot.com/2011/03/find-electric-vehicle-charging-stations.html
Research electric car stocks and green auto stocks , lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp
About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com
Point Roberts, WA - March 18, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com a leader in cleantech investor research, reports on electric car stocks and battery stocks trading for March 18th. A recent report by IDTechEx calls the hybrid and EV cars the new gold rush 2011- 2021.
With higher oil prices, the sector has had some ups and downs, with the overall market volatility. Long term- the green car enthusiasts are bullish. Just like the cars, most of the stocks in the sector are trading up and in the green this morning.
"Hybrid and Pure Electric Cars 2011-2021" and "Car Traction Batteries - The New Gold Rush 2011-2021"
Good volume growth but greater value growth The 30.6 million EVs sold in 2011 will rise to 51.3 million in 2021 but the value of the market will grow by far more because larger and more expensive vehicles are now rapidly adopting the technology. Motorcycles, military vehicles, buses and earthmovers are among them. Hybrids will rise from about 50% to about 60% of the value market through the decade. In ten years from now, a far higher percentage of the global output of light industrial vehicles, commercial vehicles and cars will be EVs. The new report gives the detail, forecasting numbers, unit value and total market value for each applicational sector with many original tables giving subsets of the data and a large number of profiles of current and planned activities of the participants. Some EV sectors were hit by the global financial meltdown but are recovering. Many sectors now benefit from the tsunami wave of government benefits, technical innovations and new models becoming available. We evaluate these aspects and the market drivers, including what users really need. Battery, motor and other technology is explained and forecasted as well. This report "Electric Vehicles 2011-2021" is a sister report to IDTechEx reports about the two most important subsectors of the EV business - "Hybrid and Pure Electric Cars 2011-2021" and "Car Traction Batteries - The New Gold Rush 2011-2021".
For more information visit http://www.researchandmarkets.com/research/a7c011/electric_vehicles
EV Sector Snapshot Morning Trading March 18th
- A123 Systems, Inc. (NasdaqGM: AONE) trading at $7.75, up 0.06 (0.78%) 10:44AM EDT
- ENER1, Inc. (NASDAQ: HEV) trading at $ $3.02, down 0.03 (0.98%) 10:45AM EDT
- Ecotality, Inc. (NasdaqCM: ECTY) trading at $3.3680, up 0.0080 (0.24%)
- EVCARCO (OTCBB: EVCA)) trading at $ 0.03
- NRG Energy, Inc.(NYSE: NRG ) at $20.45, up 0.25 (1.21%)
- Tesla Motors, Inc. (NASDAQ: TSLA) trading at $22.98, up 0.16 (0.70%) 10:47AM EDT
- UQM Technologies, Inc. (NYSE Amex: UQM) trading at $2.81, up 0.12 (4.46%) 10:30AM EDT
- ZENN MOTOR COMPANY INC. (CDNX: ZNN.V) trading at$1.92, up 0.05 (2.67%)
- Dow 11,778.90 +165.60 +1.43%
- Nasdaq 2,656.42 +39.60 +1.51%
- S&P 500 1,277.30 +20.42 +1.62%
- 10 Yr Bond(%) 3.2790% +0.0670
- Oil 100.27 +2.29 +2.34%
- Gold 1,396.00 0.00 0.00%
EVCARCO (OTC.BB: EVCA) to Showcase Latest Alternative Energy Units at Ft. Worth Auto Show
CNG Units to Be Displayed for Commercial Customers
Full news;http://www.investorideas.com/CO/EVCA/news/2011/03171.asp
Company Snapshots
EVCARCO (OTC.BB: EVCA) - Green, Electric Cars and Natural Gas Vehicles
EVCARCO (OTC.BB:EVCA) (www.evcarco.com) is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
NRG Energy, Inc., a Fortune 500 and S&P 500 Index company, owns and operates one of the country's largest and most diverse power generation portfolios. Headquartered in Princeton, NJ, the Company's power plants provide nearly 26,000 megawatts of generation capacity—enough to supply more than 20 million homes. NRG's retail businesses, Reliant Energy and Green Mountain Energy Company, combined serve more than 1.8 million residential, business, commercial and industrial customers. With investments in solar, wind and nuclear power, as well as electric vehicle infrastructure, NRG is working to help America's transition to a clean energy economy.
NRG Energy is a founding member of the Electrification Coalition, a nonpartisan, not-for-profit group of business leaders committed to promoting policies and actions that facilitate the deployment of electric vehicles on a mass scale. More information is available at www.nrgenergy.com.
About eVgo
eVgo is the nation's first privately funded, comprehensive electric vehicle ecosystem. The eVgo network gives EV owners new freedom and range confidence via home charging and fast-charging stations conveniently located at major retailers, employers and along highways across eVgo cities. eVgo allows EV owners to avoid paying large up-front costs for a home charger and provides unlimited use remote charging—all for one low monthly fee. To find out more, or to join the eVgo network, visit www.evgonetwork.com.
More News:
Find electric vehicle charging stations on Google Maps
Wednesday, March 9, 2011 at 9:30 AM
[Cross-posted from the Google.org Blog]
http://google-latlong.blogspot.com/2011/03/find-electric-vehicle-charging-stations.html
Research electric car stocks and green auto stocks , lithium stocks - with the renewable energy stocks directory Research over 1300 green stocks - Investors also have the option to access the directory as part of the Investor Ideas Investors also have the option to access the directory as part of the Investor Ideas Membership premium content that currently features an additional 10 stock directories, including the water stocks directory and all cleantech stock directories. http://www.investorideas.com/membership/
Investors - sign up for free stock alerts and investor news alerts
http://www.investorideas.com/Resources/Newsletter.asp
About Our Green Investor content:
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. Disclosure: Investorideas is compensated by featured green companies EVCARCO (OTCBB: EVCA) is a showcase stock at Investorideas.com and compensated the site 500,000 144 shares in lieu of cash compensation.
For more information contact:
Email: dvanzant@investorideas.com or Cali at cvanzant@investorideas.com
Source: www.Investorideas.com
Biotech/Pharma Stock News; BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Financial Results for 2010 and Clinical Development and Business Highlights
LINCOLNSHIRE, Ill. - March 17, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced financial results for the year ended December 31, 2010 and clinical development and business highlights.
Financial Results for 2010
As of December 31, 2010, BioSante's cash balance was approximately $38.2 million as compared to $29.9 million at December 31, 2009. Subsequently, on March 9, 2011, the company completed a registered direct offering, resulting in net proceeds of approximately $23.8 million. Consequently, on March 10, 2011, BioSante's cash balance was approximately $54 million. "We are very pleased with our progress over the last year as well as our current cash balance," said Stephen M. Simes, BioSante's president and CEO. "Through careful cash management and our financing strategy, we believe we now have removed any near-term financial risk from BioSante, and our current cash balance is sufficient to finance our operations and LibiGel clinical development well into 2012, without need for additional funds."
BioSante's net loss was $46.2 million or $0.70 per share for the year ended December 31, 2010, compared to a net loss of $47.5 million or $1.40 per share for 2009. This decrease in net loss was due primarily to transaction and non-cash technology related expenses in 2009, associated with the company's merger with Cell Genesys, Inc., offset by increased LibiGel® clinical development expenses in 2010.
LibiGel® Clinical Highlights
The increased LibiGel clinical development expenses during 2010 was the result of steady progress in BioSante's LibiGel Phase III clinical program. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product. In February 2011, the company announced completion of enrollment in the first of two LibiGel Phase III efficacy trials, and expects enrollment in the second efficacy trial to be completed in the near future. BioSante continues to expect data from the two efficacy trials in Fall 2011.
BioSante also is conducting a Phase III safety study of LibiGel which has enrolled almost 3,000 women resulting in 3,200 women-years of safety data. A maximum of 4,000 patients will be enrolled in the study and be followed for a total of five years. However, BioSante can use the safety study data as part of a New Drug Application (NDA) submission after an average of 12 months of exposure to LibiGel or placebo. The study's independent data monitoring committee (DMC) has met five times and voted unanimously each time that the study should continue as per FDA-agreed protocol, without modification.
Pipeline Updates
In addition to the LibiGel clinical program, BioSante has a number of pipeline candidates in development, including a broad portfolio of cancer vaccines. Clinical trials of BioSante's Cancer Vaccines are being conducted to treat leukemia, pancreatic cancer and breast cancer, among other cancer types. These studies are being conducted in cooperation with The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and are sponsored or funded at little or no cost to BioSante. Through March 2011, four of these cancer vaccines, the Pancreas Cancer Vaccine, Chronic Myeloid Leukemia Cancer Vaccine, Melanoma Cancer Vaccine, and Acute Myeloid Leukemia Cancer Vaccine, have received FDA Orphan Drug designations.
BioSante's pipeline also includes Bio-T-Gel™, a testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals for development and marketing. BioSante also has a licensing agreement with Pantarhei Bioscience for the development of the Pill-Plus triple component oral contraceptive which uses patented technology from BioSante. Pantarhei is engaged in several Phase II/III clinical studies with this product.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
LINCOLNSHIRE, Ill. - March 17, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) today announced financial results for the year ended December 31, 2010 and clinical development and business highlights.
Financial Results for 2010
As of December 31, 2010, BioSante's cash balance was approximately $38.2 million as compared to $29.9 million at December 31, 2009. Subsequently, on March 9, 2011, the company completed a registered direct offering, resulting in net proceeds of approximately $23.8 million. Consequently, on March 10, 2011, BioSante's cash balance was approximately $54 million. "We are very pleased with our progress over the last year as well as our current cash balance," said Stephen M. Simes, BioSante's president and CEO. "Through careful cash management and our financing strategy, we believe we now have removed any near-term financial risk from BioSante, and our current cash balance is sufficient to finance our operations and LibiGel clinical development well into 2012, without need for additional funds."
BioSante's net loss was $46.2 million or $0.70 per share for the year ended December 31, 2010, compared to a net loss of $47.5 million or $1.40 per share for 2009. This decrease in net loss was due primarily to transaction and non-cash technology related expenses in 2009, associated with the company's merger with Cell Genesys, Inc., offset by increased LibiGel® clinical development expenses in 2010.
LibiGel® Clinical Highlights
The increased LibiGel clinical development expenses during 2010 was the result of steady progress in BioSante's LibiGel Phase III clinical program. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product. In February 2011, the company announced completion of enrollment in the first of two LibiGel Phase III efficacy trials, and expects enrollment in the second efficacy trial to be completed in the near future. BioSante continues to expect data from the two efficacy trials in Fall 2011.
BioSante also is conducting a Phase III safety study of LibiGel which has enrolled almost 3,000 women resulting in 3,200 women-years of safety data. A maximum of 4,000 patients will be enrolled in the study and be followed for a total of five years. However, BioSante can use the safety study data as part of a New Drug Application (NDA) submission after an average of 12 months of exposure to LibiGel or placebo. The study's independent data monitoring committee (DMC) has met five times and voted unanimously each time that the study should continue as per FDA-agreed protocol, without modification.
Pipeline Updates
In addition to the LibiGel clinical program, BioSante has a number of pipeline candidates in development, including a broad portfolio of cancer vaccines. Clinical trials of BioSante's Cancer Vaccines are being conducted to treat leukemia, pancreatic cancer and breast cancer, among other cancer types. These studies are being conducted in cooperation with The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, and are sponsored or funded at little or no cost to BioSante. Through March 2011, four of these cancer vaccines, the Pancreas Cancer Vaccine, Chronic Myeloid Leukemia Cancer Vaccine, Melanoma Cancer Vaccine, and Acute Myeloid Leukemia Cancer Vaccine, have received FDA Orphan Drug designations.
BioSante's pipeline also includes Bio-T-Gel™, a testosterone gel for male hypogonadism, which is licensed to Teva Pharmaceuticals for development and marketing. BioSante also has a licensing agreement with Pantarhei Bioscience for the development of the Pill-Plus triple component oral contraceptive which uses patented technology from BioSante. Pantarhei is engaged in several Phase II/III clinical studies with this product.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
McKinney/Chicago
Alan Zachary
(312) 944-6784 ext. 316
azachary@mckinneychicago.com
Disclosure, Disclaimer/ BPAX is a paid advertising client on Investorideas.com (1000 per month).
Biotech Stock News Alert; Aethlon Medical, Inc. (OTCBB:AEMD) Updates Shareholders
San Diego, CA, March 17, 2011 � Investorideas.com newswire; Biotech and biodefense stock news; Aethlon Medical Shareholder Letter Aethlon Medical, Inc., (OTCBB:AEMD) disclosed that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
Website: aethlonmedical.com
To our Shareholders:
As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats. This policy shift redefines the primary strategic objective of related government agencies to be the identification and support of innovative broad-spectrum countermeasures, technologies, and platforms. This is a considerable shift from the government�s previous focus of attempting to align a single drug or vaccine countermeasure with each pathogen threat. We remain convinced that our Hemopurifier� is the most advanced broad-spectrum countermeasure, technology, or platform.
Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier� as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. While the pursuit of government grants and contracts is not our primary focus, it is difficult to ignore a growing pipeline of new and evolving opportunities to advance our science with non-dilutive capital resources.
On February 8th, we were pleased to learn that the Defense Advanced Research Projects Agency (DARPA) released a broad agency announcement (BAA) entitled: �Dialysis Like Therapeutics� (DLT). The goal of the DLT program is to develop a portable device that removes �dirty� blood from the body, separates harmful agents, and returns �clean� blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned device will be capable of removing at least 90% of unknown pathogens, toxins, and activated cells from a patient in one day. As stated in the BAA, targets for removal include viral pathogens referenced to include Hepatitis-C Virus (HCV), Human Immunodeficiency Virus (HIV), Influenza Bio-agents, Smallpox, and viral hemorrhagic fevers. As we have proven capabilities within the scope of this BAA, we plan to respond with a full proposal by April 1st.
If you are not familiar with DARPA, their mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming our national security by sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military use. Innovation sponsored by DARPA has resulted in groundbreaking discoveries and life changing advances such as the internet. DARPA envisions that the device developed under this BAA would save the lives of thousands of military patients each year.
If selected to participate in the DLT program, we would anticipate a multifaceted role that would involve teaming with other industry partners to advance our core Hemopurifier� as an innovative dialysis-like multi-use platform technology able to selectively target deleterious pathogens and toxins from the entire circulatory system. We would also seek expand the capabilities of our technology platform as the basis for a device targeting to reduce the presence of circulating factors that are precursors to sepsis. Our goal would be to reduce the occurrence of sepsis as post-sepsis treatment strategies to inhibit the inflammation process including the modulation of inflammatory cytokines have yet to be proven clinically beneficial. It is also possible that we could participate in the advancement of portable blood pump technology required under the BAA that would be deployed to treat wounded warfighters with extracorporeal device technologies including current and future iterations of our Hemopurifier� technology. Regardless of outcome, it is truly gratifying to witness therapeutic filtration being the focal point of a government contract opportunity. This is especially true when it comes from an agency as scientifically adept as DARPA. Once we complete our submission to DARPA, I will be back in touch with an update on other activities.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier� to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company�s ability to raise capital when needed, including obtaining government grants, the Company�s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier� to improve the efficacy of SOC therapy against HCV, the Company�s ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier�, the impact of government regulations, patent protection on the Company�s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company�s Securities and Exchange Commission filings.
Disclaimer /Disclosure
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Visit the profile at Investorideas.com: http://www.investorideas.com/co/aemd/
San Diego, CA, March 17, 2011 � Investorideas.com newswire; Biotech and biodefense stock news; Aethlon Medical Shareholder Letter Aethlon Medical, Inc., (OTCBB:AEMD) disclosed that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
Website: aethlonmedical.com
To our Shareholders:
As we advance our Hepatitis-C (HCV) treatment studies in India, we have also been active in our efforts to benefit from new government policies aimed at protecting U.S. civilian and military populations from bioterror and pandemic threats. This policy shift redefines the primary strategic objective of related government agencies to be the identification and support of innovative broad-spectrum countermeasures, technologies, and platforms. This is a considerable shift from the government�s previous focus of attempting to align a single drug or vaccine countermeasure with each pathogen threat. We remain convinced that our Hemopurifier� is the most advanced broad-spectrum countermeasure, technology, or platform.
Earlier this year, we were honored to be invited by The Department of Health and Humans Services (HHS) to present our Hemopurifier� as a broad-spectrum platform technology to multi-agency health officials on January 12th at the Washington Convention Center. Since this presentation, our bioterror and pandemic threat initiative has led to follow-on meetings and presentations, including a formal presentation to the Biomedical Advanced Research and Development Authority (BARDA) on February 15th. While the pursuit of government grants and contracts is not our primary focus, it is difficult to ignore a growing pipeline of new and evolving opportunities to advance our science with non-dilutive capital resources.
On February 8th, we were pleased to learn that the Defense Advanced Research Projects Agency (DARPA) released a broad agency announcement (BAA) entitled: �Dialysis Like Therapeutics� (DLT). The goal of the DLT program is to develop a portable device that removes �dirty� blood from the body, separates harmful agents, and returns �clean� blood to the body in a manner similar to dialysis treatment of kidney failure. While the device could have an impact across multiple areas of medicine, the target application for this device is sepsis. The envisioned device will be capable of removing at least 90% of unknown pathogens, toxins, and activated cells from a patient in one day. As stated in the BAA, targets for removal include viral pathogens referenced to include Hepatitis-C Virus (HCV), Human Immunodeficiency Virus (HIV), Influenza Bio-agents, Smallpox, and viral hemorrhagic fevers. As we have proven capabilities within the scope of this BAA, we plan to respond with a full proposal by April 1st.
If you are not familiar with DARPA, their mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming our national security by sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military use. Innovation sponsored by DARPA has resulted in groundbreaking discoveries and life changing advances such as the internet. DARPA envisions that the device developed under this BAA would save the lives of thousands of military patients each year.
If selected to participate in the DLT program, we would anticipate a multifaceted role that would involve teaming with other industry partners to advance our core Hemopurifier� as an innovative dialysis-like multi-use platform technology able to selectively target deleterious pathogens and toxins from the entire circulatory system. We would also seek expand the capabilities of our technology platform as the basis for a device targeting to reduce the presence of circulating factors that are precursors to sepsis. Our goal would be to reduce the occurrence of sepsis as post-sepsis treatment strategies to inhibit the inflammation process including the modulation of inflammatory cytokines have yet to be proven clinically beneficial. It is also possible that we could participate in the advancement of portable blood pump technology required under the BAA that would be deployed to treat wounded warfighters with extracorporeal device technologies including current and future iterations of our Hemopurifier� technology. Regardless of outcome, it is truly gratifying to witness therapeutic filtration being the focal point of a government contract opportunity. This is especially true when it comes from an agency as scientifically adept as DARPA. Once we complete our submission to DARPA, I will be back in touch with an update on other activities.
On behalf of our dedicated team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier� to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company�s ability to raise capital when needed, including obtaining government grants, the Company�s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the ability to achieve commercialization in India as a result of the proposed treatment program at Medanta, The Medicity Institute, whether successful or not, the ability of the Hemopurifier� to improve the efficacy of SOC therapy against HCV, the Company�s ability to manufacture its products either internally or through outside companies and to create future generations of the Hemopurifier�, the impact of government regulations, patent protection on the Company�s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company�s Securities and Exchange Commission filings.
Disclaimer /Disclosure
AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com ($one thousand five hundred per month, $five thousand per month in 144 stock)
Effective March 15, 2011
Visit the profile at Investorideas.com: http://www.investorideas.com/co/aemd/
Electric Car Stock News; EVCARCO (OTC.BB: EVCA) to Showcase Latest Alternative Energy Units at Ft. Worth Auto Show
FT. WORTH, TX - March 17, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) announced that the Ft. Worth Auto Show at the Ft. Worth Convention Center opened today and runs through Sunday. EVCARCO is displaying its current green vehicle offerings in the Green Exhibitor Section, which is dedicated to eco-friendly products.
Mack Sanders, CEO of EVCARCO, stated, "With current government regulations and the need for compliance in the area of commercial units, EVCARCO is especially proud to present CNG Units to both Government and commercial clients. The ability for a fleet to reduce emissions, reduce hard costs for fuel and the ability to present an environmentally friendly fleet is significant for our Company."
The Company will also be exhibiting its current line of electric vehicles, charging stations, and CNG Units at the Dallas Auto Show, April 7th-10th at the Dallas Convention Center."
For more information on EVCARCO, Inc., please view: www.evcarco.com
EVCARCO Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax
FT. WORTH, TX - March 17, 2011 (Investorideas.com renewable energy/green newswire) - EVCARCO, Inc. (OTCBB:EVCA) announced that the Ft. Worth Auto Show at the Ft. Worth Convention Center opened today and runs through Sunday. EVCARCO is displaying its current green vehicle offerings in the Green Exhibitor Section, which is dedicated to eco-friendly products.
Mack Sanders, CEO of EVCARCO, stated, "With current government regulations and the need for compliance in the area of commercial units, EVCARCO is especially proud to present CNG Units to both Government and commercial clients. The ability for a fleet to reduce emissions, reduce hard costs for fuel and the ability to present an environmentally friendly fleet is significant for our Company."
The Company will also be exhibiting its current line of electric vehicles, charging stations, and CNG Units at the Dallas Auto Show, April 7th-10th at the Dallas Convention Center."
For more information on EVCARCO, Inc., please view: www.evcarco.com
EVCARCO Inc. is the first automotive retail group dedicated to deploying a coast-to-coast network of environmentally friendly franchised dealerships and vehicles. EVCARCO is bringing to market the most advanced clean technologies available in plug-in electric, alternative fuel, and pre-owned hybrid vehicles.
This Press Release contains certain forward-looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Contact:
Investor Relations Contact:
Jack Eversull
The Eversull Group, Inc.
972-571-1624
214-469-2361 fax
Visit the EVCA showcase profile at Investorideas.com
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).
Request News and Info on EVCA
Disclosure, Disclaimer/ EVCA is a paid advertising client on Investorideas.com and our renewable energy portals (500,000 144 shares).
Subscribe to:
Posts (Atom)